Download PDF
Thromb Haemost 1984; 51(01): 042-044
DOI: 10.1055/s-0038-1661015
Original Article
Schattauer GmbH Stuttgart

The Inability of Propranolol and Aspirin to Inhibit the Response of Fibrinolytic Activity and Factor VIII-Antigen to Infusion of DDAVP

E J P Brommer
*   The Gaubius Institute, Health Research Division TNO, Leiden, The Netherlands
,
F H M Derkx
**   The Department of Internal Medicine, University Hospital Dijkzigt, Erasmus University, Rotterdam, The Netherlands
,
M M Barrett-Bergshoeff
*   The Gaubius Institute, Health Research Division TNO, Leiden, The Netherlands
,
M A D H Schalekamp
**   The Department of Internal Medicine, University Hospital Dijkzigt, Erasmus University, Rotterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 29 September 1983

Accepted 09 November 1983

Publication Date:
19 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

We tested the response of the fibrinolytic activity and factor VIII-antigen levels to infusion of DDAVP in healthy volunteers and we studied the influence of propranolol and aspirin on this response. After DDAVP, 0.4 μg/kg in 10 min i. v., the fibrinolytic activity of redissolved euglobulins rose from 179 to 452 mm2 (lysis area of fibrin plates); after pretreatment with propranolol, 320 mg per day during 7 days, DDAVP induced a similar rise (from 166 to 471 mm2) and after pretreatment with a single dose of aspirin, 600 mg, ingested 5 hr before the DDAVP infusion, the lysis area increased from 159 to 455 mm2

Factor VIII-antigen level increased within 60 min after DDAVP from 104 to 208%; after pretreatment with propranolol from 111 to 230% and after a single dose of aspirin, DDAVP induced a rise from 107 to 206%.

From these data we conclude that neither baseline levels nor the release of plasminogen activator or factor VIII after DDAVP infusion are influenced by β-blockade or by interference with prostaglandin synthesis.

Key Words

Aspirin - DDAVP - Fibrinolytic activity - Plasminogen activator (t-PA) - Propranolol - Prostaglandin synthesis
 

  • References

  • 1 Brozović M. Physiological mechanism in coagulation and fibrinolysis. Br Bull 1977; 33: 231-238
    PubMedGoogle Scholar
  • 2 Bloom AL, Giddings JC, Wilks CJ. Factor VIII on the vascular intima: possible importance in haemostasis and thrombosis. Nature N Biol 1973; 241: 217-219
    PubMedGoogle Scholar
  • 3 Hoyer LW, de Los Santos RP, Hoyer JR. Antihemophilic factor antigen: localization in endothelial cells by immunofluorescent microscopy. J Clin Invest 1973; 52: 2737-2744
    CrossrefPubMedGoogle Scholar
  • 4 Rijken DC, Wijngaards G, Welbergen J. Relationship between uterine tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815-830
    CrossrefPubMedGoogle Scholar
  • 5 Jaffe EA, Hoyer LW, Nachman RL. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest 1973; 52: 2757-2764
    CrossrefPubMedGoogle Scholar
  • 6 Loskutoff DJ, Edgington TS. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Nat Acad Sd USA 1977; 74: 3904-3907
    PubMedGoogle Scholar
  • 7 Cash JD, Woodfield DG. Alterations of fibrinolysis and blood coagulation. Lancet 1969; 1: 54
    PubMedGoogle Scholar
  • 8 Ingram GI C, Vaughan JonesR. Alterations of fibrinolysis and blood coagulation. Lancet 1969; 1: 310
    PubMedGoogle Scholar
  • 9 Gader AM A, Da Costa J, Cash JD. The effect of propranolol, alprenolol and practolol on the fibrinolytic and factor VIII responses to adrenaline and salbutamol in man. Thromb Res 1974; 4: 25-33
    PubMedGoogle Scholar
  • 10 Mannucri PM. Enhancement of plasminogen activator by vasopressin and adrenaline: a role of cyclic AMP. Thromb Res 1974; 4: 539-549
    CrossrefPubMedGoogle Scholar
  • 11 Tanser AR, Smellie H. Observations on adrenaline-induced fibrinolysis in man. Clin Sdence 1964; 26: 375-380
    PubMedGoogle Scholar
  • 12 Cash JR, Woodfield DG, Allan AG E. Adrenergic mechanisms in the systemic plasminogen activator response to adrenaline in man. Br J Haematol 1970; 18: 487-494
    CrossrefPubMedGoogle Scholar
  • 13 Rosing DR, Redwood DR, Brakman P, Astrup T, Epstein SE. The fibrinolytic response of man to vasoactive drugs measured in arterial blood. Thromb Res 1978; 13: 419-428
    CrossrefPubMedGoogle Scholar
  • 14 Cohen RJ, Epstein SE, Cohen LS, Dennis LH. Alterations of fibrinolysis and blood coagulation induced by exercise, and the role of beta-adrenergic-receptor stimulation. Lancet 1968; 2: 1264-1266
    PubMedGoogle Scholar
  • 15 Ingram GI C, Vaughan JonesR. The rise in clotting factor VIII induced in man by adrenaline: effect of α- and β-blockers. J Physiol 1966; 187: 447-454
    CrossrefPubMedGoogle Scholar
  • 16 Britton BJ, Wood WG, Smith M, Hawkey C, Irving MH. The effect of beta adrenergic blockade upon exercise-induced changes in blood coagulation and fibrinolysis. Thromb Haemostas 1976; 35: 396-402
    PubMedGoogle Scholar
  • 17 Korsan-Bengtsen MD, Conradson Th-B. Influence of two different beta-adrenergic blocking agents on the increase in fibrinolytic activity and factor VIII activity during submaximum and maximum exercise. Scand J Haematol 1974; 13: 377-384
    PubMedGoogle Scholar
  • 18 Gader AM A, Da Costa J, Cash JD. A new vasopressin analogue and fibrinolysis. Lancet 1973; 2: 1417-1418
    PubMedGoogle Scholar
  • 19 Mannucri PM, Åberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VII increase after vasoactive drugs. Br J Haematol 1975; 30: 81-93
    CrossrefPubMedGoogle Scholar
  • 20 Åberg M, Nilsson IM, Vilhardt H. The release of fibrinolytic activator and factor VIII after injection of DDAVP: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Cepelak V, Samama MM, Desnoyers PC. Eds Raven Press; New York: 1979. 4 92-97
    Google Scholar
  • 21 Holmberg L, Nilsson IM, Wallen P, Åstedt B. Studies of the blood plasminogen activator induced by l-desamino-8-D-arginine vasopressin with observations in von Willebrand’s disease. Proc Soc Exp Biol Med 1982; 170: 126-132
    CrossrefPubMedGoogle Scholar
  • 22 Brommer EJ P, Barrett-Bergshoeff MM, Allen RA, Schicht I, Bertina RM, Schalekamp MA D H. The use of desmopressin acetate (DDAVP) as a test of the fibrinolytic capacity of patients; analysis of responders and nonresponders. Thromb Haemostas 1982; 48: 156-161
    PubMedGoogle Scholar
  • 23 Belch JJ F, Small M, McKenzie F, Hill PA, Lowe GD O, McIntyre DE, Forbes CD, Prentice CR M. DDAVP stimulates prostacyclin production. Thromb Haemostas 1982; 47: 122-123
    PubMedGoogle Scholar
  • 24 Kluft C, Brakman P, Velhuyzen-Stolk EC. Screening of fibrinolytic activity in plasma euglobulin fractions on the fibrin plate: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC. Eds Raven Press; New York: 1976. 2 57-65
    Google Scholar
  • 25 Haverkate F, Brakman P. Fibrin plate assay: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC. Eds Raven Press; New York: 1975. 1 151-159
    Google Scholar
  • 26 Cash JD. Control mechanism of activator release: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC. Eds Raven Press; New York: 1978. 3 65-75
    Google Scholar
  • 27 Cort JH, Fischman AJ, Dodds WJ, Rand JH, Schwartz IL. New category of vasopressin receptor in the central nervous system. Int J Pept Protein Res 1981; 17: 14-22
    PubMedGoogle Scholar